Adagio Medical Holdings, Inc. reported a net loss of $6.995 million for the first quarter of 2026, a decrease from the $7.713 million loss recorded in the same period of the previous year. The company did not generate any revenue during this quarter, consistent with the prior year, as it paused commercial activities in Europe to focus on clinical trials and product development. Total operating expenses for the quarter were $5.2 million, down from $7.4 million in the first quarter of 2025, primarily due to reduced research and development costs and lower selling, general, and administrative expenses.
The company's cash and cash equivalents decreased to $12.9 million as of March 31, 2026, from $17.1 million at the end of 2025. Adagio's accumulated deficit increased to $102.6 million, reflecting ongoing operational losses since its inception. The company reported net cash used in operating activities of $4.1 million for the first quarter of 2026, a significant improvement from $7.2 million in the same period last year. This reduction in cash burn is attributed to cost-cutting measures and a strategic focus on essential clinical activities.
Adagio continues to advance its clinical programs, particularly the vCLAS™ Ventricular Ablation System, which is currently under evaluation in the FULCRUM-VT U.S. Investigational Device Exemption pivotal study. The company received Breakthrough Device designation from the FDA for this system in April 2025. Additionally, Adagio has received IDE approval to expand its trial to evaluate a next-generation version of the vCLAS system, designed to enhance usability and integration into existing workflows.
The company has also engaged in strategic financing activities, including a private placement in October 2025 that raised approximately $19 million, with potential additional proceeds from warrant exercises. Despite these efforts, Adagio's management has expressed concerns regarding its ability to continue as a going concern, indicating that existing cash reserves may not be sufficient to fund operations beyond the third quarter of 2026 without additional financing. The company plans to pursue further equity or debt financing, regulatory approvals, and cost management strategies to mitigate these risks.
About Adagio Medical Holdings, Inc.
Adagio Medical Holdings, Inc. develops and commercializes catheter-based cryoablation technologies for treating cardiac arrhythmias, primarily ventricular tachycardia. Its proprietary Ultra Low Temperature Cryoablation (ULTC) and Pulsed Field Cryoablation (PFCA) systems aim to improve ablation efficacy and safety. Serving the electrophysiology market, the company focuses on device innovation, regulatory approval, and clinical validation to address large, underserved patient populations worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.